Youssef Hafez

Dr. Youssef Hafez

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ANAhmad Basil Nasir
Ahmad Basil Nasir
YKYassine Kilani
Yassine Kilani
MAMohammad Aldiabat
Mohammad Aldiabat
OAOmar Abdelghany
Omar Abdelghany
YHYoussef Hafez
Youssef Hafez
WSWING-KIN SYN
WING-KIN SYN
Objective: To determine whether metabolic risk factors (MRFs), metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH) are associated with incident mild cognitive impairment (MCI), vascular dementia (VD), and Alzheimer disease (AD). Design: Retrospective cohort study using TriNetX (2003–2023) with Propensity score matching. Setting: Multicenter, population-based sample from 69 U.S. healthcare organizations in the TriNetX electronic health record. Participants: Adults aged ≥50 years with ≥1 outpatient visit and sufficient clinical/laboratory data. Individuals with prior diagnoses of cognitive impairment, cerebrovascular disease, advanced liver disease, malignancy, schizophrenia, or substance use disorders were excluded. Two matched cohorts were constructed: one with 3,546,833 individuals with MRFs and 3,546,833 healthy controls, and another with 525,844 individuals with MASLD/MASH and 525,844 with MRFs only. Matching was based on age, sex, race, and ethnicity. Primary and secondary outcome measures: Incident MCI, VD, and AD, identified using ICD-10 codes, assessed at 5–20-year intervals. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using logistic regression. Outcomes were prespecified. Results: Among 7,818,146 participants (mean [SD] age, 64.9 [8.8] years; 52.0% female), individuals with MRFs had higher odds of VD (OR, 1.65; 95% CI, 1.63–1.67), MCI (OR, 1.45; 95% CI, 1.42–1.48), and AD (OR, 1.21; 95% CI, 1.19–1.24) vs healthy controls. Compared to the MRF group, individuals with MASLD/MASH had lower odds of VD (OR, 0.86; 95% CI, 0.83–0.89) and AD (OR, 0.83; 95% CI, 0.78–0.88), but higher odds of MCI (OR, 1.37; 95% CI, 1.30–1.44); all p < .001. Conclusions: In this large, propensity-matched retrospective cohort study, MRFs were independently associated with significantly increased long-term odds of MCI, VD, and AD. MASLD/MASH demonstrated a divergent cognitive risk profile relative to MRFs alone—characterized by higher odds of MCI but paradoxically lower odds of VD and AD, a pattern that warrants cautious interpretation given potential competing mortality risk, survivor bias, and residual confounding. These findings suggest that MASLD/MASH is associated with a distinct cognitive trajectory, highlighting the importance of early cognitive surveillance in this population.

21 September 2026 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
YKYassine Kilani
Yassine Kilani
FHFarah Heis
Farah Heis
ADAndrew Dugaesescu
Andrew Dugaesescu
YHYoussef Hafez
Youssef Hafez
SHShadi Hamdeh
Shadi Hamdeh
MMMahmoud Y. Madi
Mahmoud Y. Madi
Background: The association between medications—including non‐steroidal anti‐inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs) and selective serotonin reuptake inhibitors (SSRIs)—and microscopic colitis (MC) remains controversial. While earlier studies suggested increased risk, more recent analyses have challenged these findings, citing methodological limitations. We evaluated the risk of MC among commonly implicated medications using a large national U.S. database. Methods: Using the TriNetX database (2014–2024), we conducted a retrospective cohort study including adults ≥ 50 years with at least one documented healthcare encounter and no prior MC or inflammatory bowel disease. Exposure was defined as ≥ 3 prescriptions within a drug class. Treatment groups (NSAIDs, PPIs, SSRIs, ACE inhibitors [ACEIs], angiotensin receptor blockers [ARBs], statins) were 1:1 propensity score‐matched (PSM) to untreated controls on age, sex, race, comorbidities and previous colonoscopy. The primary outcome was incident MC, identified by new diagnostic codes. Cox proportional hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CIs). Results: After PSM, cohorts included 907,266 NSAID, 750,009 PPI, 308,310 SSRI, 393,952 ACEI, 298,480 ARB users and 548,339 statin users. Over 2 years, MC risk was increased with NSAIDs (HR 1.15; 95% CI, 1.02–1.30), PPIs (HR 1.36; 95% CI, 1.19–1.54) and SSRIs (HR 1.52; 95% CI, 1.27–1.83). ACEIs, ARBs and statins were not associated with MC. Conclusions: In this large cohort, NSAIDs, PPIs and SSRIs were associated with an increased risk of MC, whereas no significant association was observed for ACEIs, ARBs or statins. Medication review should be considered in patients with new‐onset chronic diarrhoea.

5 October 2026 in Crohn’s & Colitis 360
Verified
Journal Article
Open access
YHYoussef Hafez
Youssef Hafez
AOAli Osman
Ali Osman
WSWING-KIN SYN
WING-KIN SYN
MSManar Shmais
Manar Shmais
Background: Inflammatory bowel disease (IBD) and hidradenitis suppurativa (HS) frequently coexist and share overlapping immune pathways, yet comparative real-world outcomes between IL-12/23 or IL-23 inhibitors and Janus kinase (JAK) inhibitors in this population remain poorly defined. Methods: We conducted a retrospective cohort study using a large, multicenter, real-world dataset. Adults (≥16 years) with IBD and HS who initiated an IL-12/23 or IL-23 inhibitor after anti-TNF therapy or a JAK inhibitor were included; patients with prior exposure to the opposing drug class were excluded. Propensity score matching (1:1) yielded 150 patients per cohort. Outcomes from 30-365 days included acute care utilization, corticosteroid use, IBD complications, and overall and hidradenitis-specific antibiotic use. Results: After propensity score matching, 300 patients were included (150 per cohort; mean age 38 years; 75.3% female). Rates of emergency department visits or hospitalization were similar between groups (RR 1.20, 95% CI, 0.82-1.77). Corticosteroid use risk was numerically higher in the IL-12/23 or IL-23 cohort (RR 1.20, 95% CI, 0.98-1.46). IBD-related complications did not differ significantly (RR 1.06, 95% CI, 0.58-1.93). Overall antibiotic use was comparable, while hidradenitis-specific antibiotic use was higher in the IL-12/23 or IL-23 cohort (RR 1.47, 95% CI, 1.11-1.95). Conclusions: In this real-world analysis, IL-12/23 or IL-23 inhibitor therapy was associated with higher hidradenitis-specific antibiotic use and numerically greater but statistically nonsignificant corticosteroid exposure, while hospitalization and IBD-related complications were comparable. These findings should be interpreted cautiously given the absence of validated disease-activity measures; prospective studies are needed to inform optimal therapeutic selection.

3 July 2026 in Cancers
Verified
Journal Article
Open access
PDF file
MEMohamed Eldesouki
Mohamed Eldesouki
ASAhmed Salem
Ahmed Salem
YHYoussef Hafez
Youssef Hafez
EIEzzElDien A. Ibrahim
EzzElDien A. Ibrahim
MYMohammed Youssef
Mohammed Youssef
ASAasma Shaukat
Aasma Shaukat
Background: The incidence of early-onset colorectal cancer (EOCRC) is rising, yet the relative contribution of metabolic, inflammatory, and laboratory abnormalities remains incompletely defined. Objectives: We compared these associations between EOCRC and late-onset colorectal cancer (LOCRC) while addressing the possibility that some laboratory abnormalities may reflect occult cancer rather than antecedent risk. Methods: We conducted a matched case–control study using the TriNetX US Network. Adults diagnosed with CRC between 2010 and 2023 were identified as EOCRC (18–49 years) or LOCRC (50–75 years). Patients with prior malignancy, inflammatory bowel disease, hereditary or familial CRC risk, or prior colectomy were excluded. Three separate analyses were performed. First, a direct EOCRC-versus-LOCRC comparison evaluated gastrointestinal symptoms during the 6 months preceding diagnosis. Second, EOCRC and LOCRC were each compared with their respective matched cancer-free controls to assess clinical, metabolic, and laboratory features during the 24 months preceding diagnosis. When multiple laboratory values were available, the most recent value preceding the index date was used. Conditional logistic regression estimated adjusted odds ratios with 95% confidence intervals, with Bonferroni correction applied for multiple comparisons. Results: The direct matched EOCRC-versus-LOCRC comparison included 7752 patients with CRC, comprising 2584 with EOCRC and 5168 with LOCRC. EOCRC more frequently presented with rectal bleeding, abdominal pain, diarrhea, iron-deficiency anemia, and weight loss. Rectal tumors were more common in EOCRC, whereas proximal tumors were more common in LOCRC. In separate control-based analyses, 3217 patients with EOCRC and 12,112 patients with LOCRC were compared with 6434 and 24,336 matched cancer-free controls, respectively. The strongest independent features associated with EOCRC were severe obesity (aOR 2.61), microcytosis (aOR 2.29), low ferritin (aOR 2.11), and elevated C-reactive protein (aOR 1.87). Similar but generally attenuated associations were observed in LOCRC. In adjusted EOCRC-versus-LOCRC analyses, obesity (aOR 1.38), metabolic syndrome (aOR 1.41), and MASH (aOR 1.22) remained more closely associated with EOCRC. Conclusions: EOCRC is associated with a distinct clinical–metabolic phenotype, with more pronounced metabolic, inflammatory, and hematologic abnormalities than LOCRC. These findings should be interpreted as hypothesis-generating prediagnostic associations, not as validated predictors or causal risk factors.